Nov 12 (Reuters) - Abeona Therapeutics Inc :
* ABEONA THERAPEUTICS® ANNOUNCES FDA ACCEPTANCE OF BLA RESUBMISSION OF PZ-CEL FOR THE TREATMENT OF RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA
* ABEONA THERAPEUTICS INC - FDA SETS PDUFA TARGET ACTION DATE OF APRIL 29, 2025
* ABEONA THERAPEUTICS INC - BLA RESUBMISSION SUPPORTED BY PHASE 3 AND PHASE 1/2A STUDIES
* ABEONA THERAPEUTICS INC - MAY RECEIVE PRIORITY REVIEW VOUCHER IF PZ-CEL APPROVED
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.